Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of PRECIOUS-01 in advanced solid tumors
NL-OMON52685Phase 1Recruiting
- Sponsor
- Tumor Immunology
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRECIOUS-01 in Nonhematologic neoplasms (3 arms), sponsored by Tumor Immunology. Primary endpoints: Safety and tolerability and Intratumoral immune modulation. Started Apr 2021; status: recruiting.
02
Drugs
PRECIOUS-01
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON52685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52685.